methylprednisolone acetate and Amyotrophy, Thenar, Of Carpal Origin

methylprednisolone acetate has been researched along with Amyotrophy, Thenar, Of Carpal Origin in 12 studies

Methylprednisolone Acetate: Methylprednisolone derivative that is used as an anti-inflammatory agent for the treatment of ALLERGY and ALLERGIC RHINITIS; ASTHMA; and BURSITIS; and for the treatment of ADRENAL INSUFFICIENCY.
methylprednisolone acetate : An acetate ester resulting from the formal condensation of the 21-hydroxy function of 6alpha-methylprednisolone compound with acetic acid.

Research

Studies (12)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

BCTQ Functional Limitations Subscale 6 Months

Comparison of BCTQ functional limitations between treatment groups at 6 months follow-up (1-5 scale, higher score indicates more functional impairment). BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 months

BCTQ Functional Limitations Subscale 6 Months (CC)

Sensitivity analysis for comparison of BCTQ function limitations between treatment groups at 6 months follow-up (scale 1-5, higher score indicates more functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 months

BCTQ Functional Limitations Subscale 6 Months (PP)

Per protocol analysis for comparison of BCTQ functional limitations between treatment groups at 6 months follow-up (scale 1-5, higher score indicates more functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 months

BCTQ Functional Limitations Subscale 6 Weeks

Comparison of BCTQ functional limitations between treatment groups at 6 weeks follow-up (1-5 scale, higher score indicates more severe functional impairment). BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Functional Limitations Subscale 6 Weeks (CC)

Sensitivity analysis for comparison of overall BCTQ between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Functional Limitations Subscale 6 Weeks (PP)

"Per protocol analysis for comparison of BCTQ functional limitations between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more functional impairment) on participants with complete data.~BCTQ: Boston Carpal Tunnel Questionnaire" (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity and Functional Limitations 6 Months

Comparison of overall BCTQ between treatment groups at 6 months follow-up (1-5 scale, higher score indicates more severe symptoms and functional impairment). BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 months

BCTQ Symptom Severity and Functional Limitations 6 Months (CC)

Sensitivity analysis for comparison of overall BCTQ between treatment groups at 6 months follow-up (scale 1-5, higher score indicates more severe symptoms and functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 months

BCTQ Symptom Severity and Functional Limitations 6 Months (PP)

Per protocol analysis for comparison of overall BCTQ between treatment groups at 6 months follow-up (scale 1-5, higher score indicates more severe symptoms and functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 months

BCTQ Symptom Severity and Functional Limitations 6 Weeks (Complete Case Analysis (CC))

Sensitivity analysis for comparison of overall BCTQ between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more severe symptoms and functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity and Functional Limitations 6 Weeks (Per-Protocol Analysis (PP))

Per protocol analysis for comparison of overall BCTQ between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more severe symptoms and functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Did Not Receive the Intervention of Their Preference)

Subgroup analysis was performed in patients who did not receive the intervention of their preference. Comparison of overall BCTQ between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more severe symptoms and functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Did Not State a Preference of Intervention)

Subgroup analysis was performed in patients who did not state a preference of intervention. Comparison of overall BCTQ between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more severe symptoms and functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Preferred Injection)

Subgroup analysis was performed in patients who preferred injection. Comparison of overall BCTQ between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more severe symptoms and functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity and Functional Limitations 6 Weeks (SG, Preferred Splint)

Subgroup analysis was performed in patients who preferred splint. Comparison of overall BCTQ between treatment groups at 6 weeks follow-up (higher score indicates more severe symptoms and functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity and Functional Limitations 6 Weeks (Subgroup Analysis (SG), Intervention of Their Preference)

Subgroup analysis was performed in patients who were allocated the intervention of their preference. Comparison of overall BCTQ between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more severe symptoms and functional impairment) on participants with complete data. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity and Functional Limitations Over 24 Months: 12 Months

Comparison of overall BCTQ between treatment groups across all time points (6 weeks, 6-, 12-, and 24 month follow-up). Scale 1-5, higher score indicates more severe symptoms and functional impairment). Results are presented at 12 months. BCTQ: Boston Carpal Tunnel Questionnaire. (NCT02038452)
Timeframe: 12 months

BCTQ Symptom Severity and Functional Limitations Over 24 Months: 6 Months

Comparison of overall BCTQ between treatment groups across all time points (6 weeks, 6-, 12-, and 24 month follow-up. Scale 1-5, higher score indicates more severe symptoms and functional impairment. Results are presented at 6 months. BCTQ: Boston Carpal Tunnel Questionnaire. (NCT02038452)
Timeframe: 6 months

BCTQ Symptom Severity and Functional Limitations Over 24 Months: 6 Weeks

Comparison of overall BCTQ between treatment groups across all time points (6 weeks, 6-, 12-, and 24 month follow-up). Scale 1-5, higher score indicates more severe symptoms and functional impairment. Results are presented at 6 weeks. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity Subscale 6 Months

Comparison of BCTQ symptom severity between treatment groups at 6 months follow-up (1-5 scale, higher score indicates more severe symptoms). BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 months

BCTQ Symptom Severity Subscale 6 Months (CC)

"Sensitivity analysis for comparison of BCTQ symptom severity between treatment groups at 6 months follow-up (scale 1-5, higher score indicates more severe symptoms) on participants with complete data. BCTQ:~Boston Carpal Tunnel Questionnaire" (NCT02038452)
Timeframe: 6 months

BCTQ Symptom Severity Subscale 6 Months (PP)

"Per protocol analysis for comparison of BCTQ symptom severity between treatment groups at 6 months follow-up (scale 1-5, higher score indicates more severe symptoms) on participants with complete data. BCTQ:~Boston Carpal Tunnel Questionnaire" (NCT02038452)
Timeframe: 6 months

BCTQ Symptom Severity Subscale 6 Weeks

Comparison of BCTQ symptom severity between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more severe symptoms). BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity Subscale 6 Weeks (CC)

"Sensitivity analysis for comparison of BCTQ symptom severity between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more severe symptoms) on participants with complete data. BCTQ:~Boston Carpal Tunnel Questionnaire" (NCT02038452)
Timeframe: 6 weeks

BCTQ Symptom Severity Subscale 6 Weeks (PP)

"Per protocol analysis for comparison of BCTQ symptom severity between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more severe symptoms) on participants with complete data. BCTQ:~Boston Carpal Tunnel Questionnaire" (NCT02038452)
Timeframe: 6 weeks

Hand-wrist Pain Intensity 6 Months

Comparison of pain scores between treatment groups at 6 months follow-up. 0-10 scale, higher score indicates more pain. (NCT02038452)
Timeframe: 6 months

Hand-wrist Pain Intensity 6 Months (CC)

Sensitivity analysis for comparison of pain scores between treatment groups at 6 months follow-up (scale 0-10, higher score indicates more pain) on participants with complete data. (NCT02038452)
Timeframe: 6 months

Hand-wrist Pain Intensity 6 Months (PP)

Per protocol analysis for comparison of pain scores between treatment groups at 6 months follow-up (scale 0-10, higher score indicates more pain) on participants with complete data. (NCT02038452)
Timeframe: 6 months

Hand-wrist Pain Intensity 6 Weeks

Comparison of pain scores between treatment groups at 6 weeks follow-up (0-10 scale, higher score indicates more pain). (NCT02038452)
Timeframe: 6 weeks

Hand-wrist Pain Intensity 6 Weeks (CC)

Sensitivity analysis for comparison of pain scores between treatment groups at 6 weeks follow-up (scale 0-10, higher score indicates more pain) on participants with complete data. (NCT02038452)
Timeframe: 6 weeks

Hand-wrist Pain Intensity 6 Weeks (PP)

Per protocol analysis for comparison of pain scores between treatment groups at 6 weeks follow-up (higher score indicates more pain) on participants with complete data. (NCT02038452)
Timeframe: 6 weeks

Hand-wrist Pain Intensity Over 24 Months: 12 Months

Comparison of pain scores between treatment groups across all time points (6 weeks, 6-, 12-, and 24 month follow-up). Scale 0-10, higher score indicates more pain. Results are presented at 12 months. (NCT02038452)
Timeframe: 12 months

Hand-wrist Pain Intensity Over 24 Months: 24 Months

Comparison of pain scores between treatment groups across all time points (6 weeks, 6-, 12-, and 24 month follow-up). Scale 0-10, higher score indicates more pain. Results are presented at 24 months. (NCT02038452)
Timeframe: 24 months

Hand-wrist Pain Intensity Over 24 Months: 6 Months

Comparison of pain scores between treatment groups across all time points (6 weeks, 6-, 12-, and 24 month follow-up). Scale 0-10, higher score indicates more pain. Results are presented at 6 months. (NCT02038452)
Timeframe: 6 months

Hand-wrist Pain Intensity Over 24 Months: 6 Weeks

Comparison of pain scores between treatment groups across all time points (6 weeks, 6-, 12-, and 24 month follow-up). Scale 0-10, higher score indicates more pain. Results are presented at 6 weeks. (NCT02038452)
Timeframe: 6 weeks

NHS Cost Differences at 12 Months

Cost of interventions at 12 months (NCT02038452)
Timeframe: 12 months

NHS Cost Differences at 24 Months

Cost of interventions at 24 months (NCT02038452)
Timeframe: 24 months

NHS Cost Differences at 6 Months

Cost of interventions at 6 months (NCT02038452)
Timeframe: 6 months

NHS Cost Differences at 6 Months (CC)

Complete case analysis on the cost of interventions at 6 months (NCT02038452)
Timeframe: 6 months

QALYS at 12 Months (Cross-walk Tariff)

"The Quality Adjusted Life Years (QALYs) is a measure of the state of health of a person/group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. QALYs are calculated by estimating the years of life remaining for a patient following a particular treatment/intervention and weighting each year with a quality-of-life score (on a 0 to 1 scale). It is often measured in terms of the person's ability to carry out the activities of daily life and freedom from pain and mental disturbance. The QALY does not have a maximum score.~Cross-walk tariff: Crosswalk value sets were developed from a study of respondents who completed both the EQ-5D-3L and EQ-5D-5L. The crosswalk used a non-parametric response mapping method to predict values that are linked to the EQ-5D-3L value set. In short, the cross-walk tariff maps EQ-5D-5L values." (NCT02038452)
Timeframe: 12 months

QALYS at 24 Months (Cross-walk Tariff)

"The Quality Adjusted Life Years (QALYs) is a measure of the state of health of a person/group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. QALYs are calculated by estimating the years of life remaining for a patient following a particular treatment/intervention and weighting each year with a quality-of-life score (on a 0 to 1 scale). It is often measured in terms of the person's ability to carry out the activities of daily life and freedom from pain and mental disturbance. The QALY does not have a maximum score.~Cross-walk tariff: Crosswalk value sets were developed from a study of respondents who completed both the EQ-5D-3L and EQ-5D-5L. The crosswalk used a non-parametric response mapping method to predict values that are linked to the EQ-5D-3L value set. In short, the cross-walk tariff maps EQ-5D-5L values." (NCT02038452)
Timeframe: 24 months

QALYS at 6 Months (Cross-walk Tariff)

"The Quality Adjusted Life Years (QALYs) is a measure of the state of health of a person/group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. QALYs are calculated by estimating the years of life remaining for a patient following a particular treatment/intervention and weighting each year with a quality-of-life score (on a 0 to 1 scale). It is often measured in terms of the person's ability to carry out the activities of daily life and freedom from pain and mental disturbance. The QALY does not have a maximum score.~Cross-walk tariff: Crosswalk value sets were developed from a study of respondents who completed both the EQ-5D-3L and EQ-5D-5L. The crosswalk used a non-parametric response mapping method to predict values that are linked to the EQ-5D-3L value set. In short, the cross-walk tariff maps EQ-5D-5L values." (NCT02038452)
Timeframe: 6 months

Secondary: BCTQ Symptom Severity and Functional Limitations Over 24 Months: 24 Months

Comparison of overall BCTQ between treatment groups across all time points (6 weeks, 6-, 12-, and 24 month follow-up). Scale 1-5, higher score indicates more severe symptoms and functional impairment. Results are presented at 24 months. BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 24 months

Symptom Severity and Limitations in Hand Function as Assessed by the BCTQ 6 Weeks

Comparison of overall BCTQ between treatment groups at 6 weeks follow-up (scale 1-5, higher score indicates more severe symptoms and functional impairment). BCTQ: Boston Carpal Tunnel Questionnaire (NCT02038452)
Timeframe: 6 weeks

Trials

9 trials available for methylprednisolone acetate and Amyotrophy, Thenar, Of Carpal Origin

Other Studies

3 other studies available for methylprednisolone acetate and Amyotrophy, Thenar, Of Carpal Origin